Sichuan Huiyu Pharmaceutical Inkomsten in het verleden
Verleden criteriumcontroles 3/6
Sichuan Huiyu Pharmaceutical's earnings have been declining at an average annual rate of -19.8%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 7.4% per year. Sichuan Huiyu Pharmaceutical's return on equity is 7%, and it has net margins of 24.8%.
Belangrijke informatie
-19.8%
Groei van de winst
-36.5%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 10.9% |
| Inkomstengroei | -7.4% |
| Rendement op eigen vermogen | 7.0% |
| Nettomarge | 24.8% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Sichuan Huiyu Pharmaceutical's (SHSE:688553) Promising Earnings May Rest On Soft Foundations
Nov 02
Sichuan Huiyu Pharmaceutical Co., Ltd. (SHSE:688553) Stock Catapults 38% Though Its Price And Business Still Lag The Market
Oct 29Here's Why Sichuan Huiyu Pharmaceutical (SHSE:688553) Can Manage Its Debt Responsibly
Sep 29Sichuan Huiyu Pharmaceutical (SHSE:688553) Has A Pretty Healthy Balance Sheet
Jun 07Sichuan Huiyu Pharmaceutical Co., Ltd.'s (SHSE:688553) 33% Share Price Surge Not Quite Adding Up
Mar 07Opbrengsten en kosten
Hoe Sichuan Huiyu Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 1,120 | 278 | 509 | 309 |
| 30 Jun 24 | 1,009 | 136 | 469 | 320 |
| 31 Mar 24 | 932 | 148 | 438 | 322 |
| 31 Dec 23 | 927 | 140 | 440 | 341 |
| 30 Sep 23 | 932 | 103 | 487 | 351 |
| 30 Jun 23 | 1,111 | 148 | 590 | 354 |
| 31 Mar 23 | 1,265 | 168 | 688 | 372 |
| 31 Dec 22 | 1,493 | 249 | 812 | 356 |
| 30 Sep 22 | 1,652 | 294 | 902 | 341 |
| 30 Jun 22 | 1,772 | 358 | 981 | 309 |
| 31 Mar 22 | 1,863 | 430 | 1,020 | 272 |
| 31 Dec 21 | 1,824 | 446 | 972 | 248 |
| 30 Sep 21 | 1,781 | 478 | 1,096 | 213 |
| 30 Jun 21 | 1,664 | 439 | 1,199 | 199 |
| 31 Mar 21 | 1,537 | 405 | 834 | 119 |
| 31 Dec 20 | 1,364 | 343 | 771 | 89 |
| 31 Dec 19 | 707 | 177 | 390 | 56 |
| 31 Dec 18 | 54 | -22 | 57 | 39 |
Kwaliteitswinsten: 688553 has a large one-off gain of CN¥179.2M impacting its last 12 months of financial results to 30th September, 2024.
Groeiende winstmarge: 688553's current net profit margins (24.8%) are higher than last year (11%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 688553's earnings have declined by 19.8% per year over the past 5 years.
Versnelling van de groei: 688553's earnings growth over the past year (171.2%) exceeds its 5-year average (-19.8% per year).
Winst versus industrie: 688553 earnings growth over the past year (171.2%) exceeded the Pharmaceuticals industry -1.2%.
Rendement op eigen vermogen
Hoge ROE: 688553's Return on Equity (7%) is considered low.